<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The blood coagulation system has been shown to be activated in <z:hpo ids='HP_0011011'>subacute</z:hpo> exacerbations of <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger disease</z:e> (BD) </plain></SENT>
<SENT sid="1" pm="."><plain>In our previous study, the antithrombin drug argatroban t ameliorated the neurological exacerbations in a BD patient with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
<SENT sid="2" pm="."><plain>We have further examined the therapeutic efficacy of argatroban in 3 BD patients with <z:hpo ids='HP_0011011'>subacute</z:hpo> exacerbations, but without any immune-mediated prothrombotic complications </plain></SENT>
<SENT sid="3" pm="."><plain>In 1 out of these 4 patients, treatment with <z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel, an antiplatelet drug was applied, but was ineffective </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patients, argatroban treatment reduced the levels of the hemostatic markers, with a corresponding improvement in <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e> and gait disorders </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest that the antithrombin effect is true also for BD patients not compromised by the immune-mediated prothrombotic condition </plain></SENT>
</text></document>